SlideShare ist ein Scribd-Unternehmen logo
1 von 28
 
Treatment may be worse than the disease
During the 1990’s, the deaths of two healthy volunteers in the US made their way to the highest political levels  and forced a review of protection of human subjects.   Ellen Roche 24 year old Healthy Volunteer Asthma study Jesse Gelsing er 18  year old   Healthy Volunteer Genetic Study
In March of 1994, the U.S. Office of Research Integrity announced that Dr. Roger Poisson from Montreal admitted having falsified data (99 cases) in a breast cancer clinical trial sponsored by the U.S. National Cancer Institute (NCI). This well-intended falsification compromised the contribution of hundreds of women enrolled in the protocol as all data from the 389 patients enrolled by Dr Poisson were removed from the analysis. Dr. Roger Poisson
 
We need sound science, ethics and safety in clinical trials to sustain the trust of government, public and, especially, the research subjects.
Limitations of addressing Patient Safety in clinical trials  ,[object Object],[object Object],[object Object],[object Object]
Thus, in order to have complete assessment of the drug in real life setting, safety reporting in post-authorisation era or pharmacovigilance is equally important.
Legal Basis of Volume 9A ,[object Object],[object Object]
Structure of Volume 9A ,[object Object],[object Object],[object Object],[object Object]
Part I - Roles & Responsibilities of the MAH ,[object Object],[object Object],[object Object]
EU Qualified Person for Pharmacovigilance ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],EU Qualified Person for Pharmacovigilance
Responsibilities of MAH ,[object Object],[object Object],[object Object],[object Object],[object Object],I have the drug license
Detailed Description of the PV System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Pharmacovigilance Inspections ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Risk Management System ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Safety Reporting in Post-authorisation period ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Safety Reporting in Post-authorisation period ,[object Object],[object Object],[object Object],[object Object]
Post-Authorisation Safety Studies   ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Risk-Benefit Assessment ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Part II – Undertaking of PV activity by  Competent Authorities and the Agency ,[object Object],[object Object],[object Object],[object Object]
Rapid Alert and Non-Urgent Information System in Pharmacovigilance ,[object Object],[object Object],[object Object]
Part III – Electronic exchange of PV information in the EU ,[object Object],[object Object],[object Object],[object Object]
Part IV – Direct Healthcare Professional Communications ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
PV Regulatory Environment in the US and Japan ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object]
Final thoughts ,[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],[object Object],Study Protocol : PRC/CRD/33/08  Capecitabine 500 mg tablets
 

Weitere ähnliche Inhalte

Was ist angesagt?

Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in us
Vinod Raj
 
Medical device clinical evaluation
Medical device clinical evaluationMedical device clinical evaluation
Medical device clinical evaluation
Malesh M
 

Was ist angesagt? (20)

Safety Reports: PBRER / PSUR
Safety Reports: PBRER / PSURSafety Reports: PBRER / PSUR
Safety Reports: PBRER / PSUR
 
GHTF
GHTFGHTF
GHTF
 
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptxCLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
CLINICAL INVESTIGATION AND EVALUATION OF MEDICAL DEVICES AND.pptx
 
IDE Application Process and Best Practices
IDE Application Process and Best PracticesIDE Application Process and Best Practices
IDE Application Process and Best Practices
 
20210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr202120210413 nvfg acs iso14155 13_apr2021
20210413 nvfg acs iso14155 13_apr2021
 
Who prequalification program
Who prequalification programWho prequalification program
Who prequalification program
 
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
Fda guidance for pharmaceutical post marketing reporting   professor pirouziFda guidance for pharmaceutical post marketing reporting   professor pirouzi
Fda guidance for pharmaceutical post marketing reporting professor pirouzi
 
PSUR
PSURPSUR
PSUR
 
21 cfr part 50
21 cfr part 5021 cfr part 50
21 cfr part 50
 
Ich gcp
Ich gcpIch gcp
Ich gcp
 
Periodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changesPeriodic safety update reports – gvp guidelines and changes
Periodic safety update reports – gvp guidelines and changes
 
Regulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in usRegulatory approval process for invitro diagnostics in us
Regulatory approval process for invitro diagnostics in us
 
Fda Acceptance Of Foreign Clinical Trial Data Feb 2009
Fda Acceptance Of Foreign Clinical Trial Data Feb 2009Fda Acceptance Of Foreign Clinical Trial Data Feb 2009
Fda Acceptance Of Foreign Clinical Trial Data Feb 2009
 
EUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCYEUROPEAN MEDICAL AGENCY
EUROPEAN MEDICAL AGENCY
 
Cfr 21 part 312
Cfr 21 part 312 Cfr 21 part 312
Cfr 21 part 312
 
International Medical Device Regulators Forum
International Medical Device Regulators ForumInternational Medical Device Regulators Forum
International Medical Device Regulators Forum
 
Plasma drug file and TSE/ BSE evaluation
Plasma drug file and TSE/ BSE evaluationPlasma drug file and TSE/ BSE evaluation
Plasma drug file and TSE/ BSE evaluation
 
Pharmacovigilance "Module I" Pharmacovigilance system & their quality system
Pharmacovigilance "Module I" Pharmacovigilance system & their quality systemPharmacovigilance "Module I" Pharmacovigilance system & their quality system
Pharmacovigilance "Module I" Pharmacovigilance system & their quality system
 
GMDNS, UDI, barcodes and more...
GMDNS, UDI, barcodes and more...GMDNS, UDI, barcodes and more...
GMDNS, UDI, barcodes and more...
 
Medical device clinical evaluation
Medical device clinical evaluationMedical device clinical evaluation
Medical device clinical evaluation
 

Andere mochten auch

Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
Ravindra Kumar
 
Top 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answersTop 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answers
tonychoper3006
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilance
Nahla Amin
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Until ROI
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice In
clarityeye
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlines
chandroo80
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilance
Bhaswat Chakraborty
 

Andere mochten auch (20)

Basics Of Pharmacovigilance
Basics Of PharmacovigilanceBasics Of Pharmacovigilance
Basics Of Pharmacovigilance
 
Pharmacovigilance ppt
Pharmacovigilance pptPharmacovigilance ppt
Pharmacovigilance ppt
 
Pharmacovigilance full information
Pharmacovigilance full informationPharmacovigilance full information
Pharmacovigilance full information
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Top 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answersTop 10 pharmacovigilance officer interview questions and answers
Top 10 pharmacovigilance officer interview questions and answers
 
Pharmacovigilance
PharmacovigilancePharmacovigilance
Pharmacovigilance
 
Causality assessment scales
Causality assessment scalesCausality assessment scales
Causality assessment scales
 
Introduction to pharmacovigilance
Introduction to pharmacovigilanceIntroduction to pharmacovigilance
Introduction to pharmacovigilance
 
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
Volume 9 A Guidelines On Pharmacovigilance by Dr. Siddharth S Chachad, Medica...
 
MAGI Presentation
MAGI PresentationMAGI Presentation
MAGI Presentation
 
Pharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspectivePharmacovigilance - a regulator's perspective
Pharmacovigilance - a regulator's perspective
 
Acceleration Brochure Japanese
Acceleration Brochure JapaneseAcceleration Brochure Japanese
Acceleration Brochure Japanese
 
Pharmacovigilance Practice In
Pharmacovigilance Practice InPharmacovigilance Practice In
Pharmacovigilance Practice In
 
ICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guidelineICH pharmacovigilance planning, an efficacy guideline
ICH pharmacovigilance planning, an efficacy guideline
 
Pharmacovigilance Workshop
Pharmacovigilance WorkshopPharmacovigilance Workshop
Pharmacovigilance Workshop
 
Spontaneous reporting
Spontaneous reporting Spontaneous reporting
Spontaneous reporting
 
Pharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlinesPharmacovigilance and ICH guidlines
Pharmacovigilance and ICH guidlines
 
FDA News Presentation
FDA News PresentationFDA News Presentation
FDA News Presentation
 
PSUR Requirements
PSUR RequirementsPSUR Requirements
PSUR Requirements
 
Data mining in pharmacovigilance
Data mining in pharmacovigilanceData mining in pharmacovigilance
Data mining in pharmacovigilance
 

Ähnlich wie Volume 9 A Guidelines On Pharmacovigilance[1]

Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
Until ROI
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
bdvfgbdhg
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
bdvfgbdhg
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
BharatRRDesai
 
post marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTSpost marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTS
PrakashGoudanavar
 

Ähnlich wie Volume 9 A Guidelines On Pharmacovigilance[1] (20)

conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products  conduct of Pharmacovigilance for centrally authorized products
conduct of Pharmacovigilance for centrally authorized products
 
Analysing the EU PVG regulations
Analysing the EU PVG regulationsAnalysing the EU PVG regulations
Analysing the EU PVG regulations
 
3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx3..Post marketing surveillance.pptx
3..Post marketing surveillance.pptx
 
Common arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilanceCommon arab guidelines in pharmacovigilance
Common arab guidelines in pharmacovigilance
 
Safety report filing
Safety report filingSafety report filing
Safety report filing
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Post marketing servillence
Post marketing servillencePost marketing servillence
Post marketing servillence
 
Regulatory requirements of eu & mhra trilok
Regulatory requirements of eu & mhra  trilokRegulatory requirements of eu & mhra  trilok
Regulatory requirements of eu & mhra trilok
 
pharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNIONpharmacovigilance in INDIA,US,EUROPEAN UNION
pharmacovigilance in INDIA,US,EUROPEAN UNION
 
Dossier on drug safety
Dossier on drug safetyDossier on drug safety
Dossier on drug safety
 
Dossier on Drug Safety.
Dossier on Drug Safety.Dossier on Drug Safety.
Dossier on Drug Safety.
 
Regulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptxRegulatory Agencies EU and MHRA.pptx
Regulatory Agencies EU and MHRA.pptx
 
Regulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGARegulatory requirement of EU, MHRA and TGA
Regulatory requirement of EU, MHRA and TGA
 
European Clinical Trial Safety Focus
European  Clinical Trial Safety FocusEuropean  Clinical Trial Safety Focus
European Clinical Trial Safety Focus
 
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptxREGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
REGULATORY REQUIREMENTS OF EU, MHRA, TGA & ROW COUNTRIES.pptx
 
pharmacovigilance study
pharmacovigilance studypharmacovigilance study
pharmacovigilance study
 
POST MARKETING SURVILLANCE
 POST  MARKETING SURVILLANCE POST  MARKETING SURVILLANCE
POST MARKETING SURVILLANCE
 
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
Safety Monitoring and Reporting in Clinical Trials DIA Poster 2015
 
post marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTSpost marketing surveillance OF DRUG PRODUCTS
post marketing surveillance OF DRUG PRODUCTS
 
Dcgi adverse event
Dcgi adverse eventDcgi adverse event
Dcgi adverse event
 

Volume 9 A Guidelines On Pharmacovigilance[1]

  • 1.  
  • 2. Treatment may be worse than the disease
  • 3. During the 1990’s, the deaths of two healthy volunteers in the US made their way to the highest political levels and forced a review of protection of human subjects. Ellen Roche 24 year old Healthy Volunteer Asthma study Jesse Gelsing er 18 year old Healthy Volunteer Genetic Study
  • 4. In March of 1994, the U.S. Office of Research Integrity announced that Dr. Roger Poisson from Montreal admitted having falsified data (99 cases) in a breast cancer clinical trial sponsored by the U.S. National Cancer Institute (NCI). This well-intended falsification compromised the contribution of hundreds of women enrolled in the protocol as all data from the 389 patients enrolled by Dr Poisson were removed from the analysis. Dr. Roger Poisson
  • 5.  
  • 6. We need sound science, ethics and safety in clinical trials to sustain the trust of government, public and, especially, the research subjects.
  • 7.
  • 8. Thus, in order to have complete assessment of the drug in real life setting, safety reporting in post-authorisation era or pharmacovigilance is equally important.
  • 9.
  • 10.
  • 11.
  • 12.
  • 13.
  • 14.
  • 15.
  • 16.
  • 17.
  • 18.
  • 19.
  • 20.
  • 21.
  • 22.
  • 23.
  • 24.
  • 25.
  • 26.
  • 27.
  • 28.  

Hinweis der Redaktion

  1. Ensure u hv a DDPVS ready, correct resources, processes are clearly documented, QC is built in, agreements in place
  2. Regulation EC) No 726/2004 and Directive 2001/83/EC
  3. Unknown = Unexpected US – Safety reporting requirements are specified in Title 21